ELMO3

Across TCGA pan-cancer cohorts, ELMO3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ELMO3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ELMO3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ELMO3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where ELMO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.456	0.908	.002	20	view →
LSCC	OS	Tertile	All	0.825	0.985	.003	14	view →
LUAD	DFS	Tertile	II,III,IV	0.324	0.744	.014	7	view →
HNSC	DFS	Median	All	0.835	0.701	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ELMO3–PDAC (OS)

Open the PDAC breakdown →